[Corrections] Correction to Lancet Diabetes & Endocrinology 2026; 14: 105–08

Yoo SGK, Teufel F, Theilmann M, et al. GLP-1 receptor agonists for obesity: eligibility across 99 countries. Lancet Diabetes & Endocrinology 2026; 14: 105–08—In this Correspondence, the corresponding author's email address should have been syoo@georgeinstitute.org.au. This correction has been made to the online version as of Jan 12, 2026.